Alnylam heads into its third-quarter report with a credibility question rather than a demand question. Three months ago the company cut its 2026 TTR revenue outlook by roughly $200 million at the midpoint, to $4.2 billion to $4.5 billion, even as US demand growth more than doubled from the first quarter and Amvutra crossed $1 billion in quarterly sales for the first time. Management acknowledged it had set the original guidance too high, mistaking a burst of pent-up second-line demand in 2025 for a durable trend. This report is the first real test of whether the reset bar is conservative enough to clear, or whether the normalization story has further to run.
Wall Street expects earnings of $1.67 per share on revenue of about $1.45 billion. That revenue figure would represent 16.1% growth from a year ago and a sizable step up from the $1.29 billion reported last quarter, so consensus is clearly leaning on continued sequential momentum. Earnings, by contrast, are expected to fall 9.2% from the year-ago $1.84. That divergence matters. Product gross margin slid to 75% last quarter from 80% in the first quarter as the royalty owed to Sanofi climbs with Amvutra volume, and modest net price erosion in the US plus ex-US pricing pressure from cardiomyopathy launches add to the drag. Revenue growth that does not translate into earnings growth is the uncomfortable trade-off of scaling a royalty-bearing product.
The most important operating signal is the composition of TTR demand. Management said first-line starts now account for about 80% of category growth, a meaningful shift from the more balanced mix it described earlier in the year, and the prescriber base expanded to more than 1,700 new prescribers since launch. If US demand growth holds near the second quarter's $129 million pace and first-line share keeps rising, the guidance cut starts to look like a one-time cleanup rather than the first leg of a downtrend. A sharp sequential deceleration, or evidence that second-line softness is still deepening, would undercut that reading and invite questions about whether the lowered range is still too ambitious.
Margins are the second swing factor. Another step down below 75% would suggest the Sanofi royalty headwind is accelerating faster than volume can offset, while stabilization would help the earnings line close the gap with revenue. The collaboration and royalty stream offers some cushion here, since management lifted that outlook to $575 million to $625 million on Leqvio royalties and Roche reimbursement. Any further upward drift there could help explain a beat even if product revenue merely lands in line. Investors should also listen for updates on the B1 deal for China and Macau and on how management frames the Triton-CM program for nucresiran after the eplontersen combination failure raised read-through concerns.
Sentiment has soured going in. Bearish readings deepened to roughly 40% from about 29% ahead of last quarter, and the stock has gained only 2.5% since the last report, trailing the S&P 500 by two percentage points. At about $231, shares sit in the middle of a post-earnings range of roughly $198 to $272, well below the 200-day moving average near $293 and far beneath the $262 to $380 band of the prior quarter. That is a substantial de-rating, which arguably lowers the bar, but it also reflects a market that no longer gives management the benefit of the doubt on guidance.
Ultimately, the quarter will be judged on whether Alnylam reaffirms its reduced TTR range with demand data that look accelerating rather than merely stable. A clean reaffirmation backed by strong first-line growth and steady margins would support the view that the fundamentals never broke. Another trim, or a further margin slide, would suggest the reset was not the final one.